Clinical trials: completed, sponsored by Bayer
Vasomotor Symptoms, Hot Flashes
Low-dose Hormone Therapy for Relief of Vasomotor Symptoms
The purpose of this study is to determine the lowest effective dose of the study drug for the relief of moderate to severe vasomotor symptoms in postmenopausal women for 12 weeks.
- Trial name
- NCT00446199
- Testing
- 0.5mg DRSP / 0.5mg E2 (BAY86-4891), 0.25mg DRSP / 0.5mg E2 (BAY86-4891), Estradiol (E2 0.3mg)
- Where
- 76 sites in United States
- Volunteers
- 735 people
- Sponsor
- Bayer
Erectile Dysfunction, Spinal Cord Injury
Assess Efficacy in Subjects With Traumatic Spinal Cord Injury
Assess efficacy of Vardenafil in patients with traumatic spinal cord injury
- Trial name
- LEMDE (NCT00667966)
- Testing
- Vardenafil (Levitra, BAY 38-9456), 10 mg, Vardenafil (Levitra, BAY 38-9456), 20 mg
- Where
- 2 sites in Spain
- Volunteers
- 45 people
- Sponsor
- Bayer
Known or Suspected Focal Liver Lesions
Efficacy and Safety of Primovist in Chinese Patients
Participants who had been diagnosed or suspected by doctors to have focal liver lesions that need further evaluation in order to make an accurate diagnosis.
- Trial name
- NCT00526188
- Testing
- Gadoxetic Acid Disodium (Primovist, BAY86-4873)
- Where
- 6 sites in China
- Volunteers
- 234 people
- Sponsor
- Bayer
Atrial Fibrillation
Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion
A study for patients with abnormal heart rhythm (atrial fibrillation) who need to undergo cardioversion (procedure to restore normal heart rhythm).
- Trial name
- X-VERT (NCT01674647)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Vitamin K antagonist (VKA)
- Where
- 178 sites in United States, Belgium and 15 more
- Volunteers
- 1,504 people
- Sponsor
- Bayer
Pneumonia
A Phase III Study to Evaluate the Safety, Efficacy and Pharmacokinetics/Pharmacodynamics of BAYQ3939 in Patients With Bacterial Pneumonia
The main objective of this study is to investigate the safety, pharmacokinetics (PK) and the relationship between PK and pharmacodynamics (Minimum Inhibitory Concentration [MIC] and Mutant Prevention Concentration [MPC]) of…
- Trial name
- NCT01561794
- Testing
- Ciprofloxacin (Cipro, BAYQ3939)
- Where
- 20 sites in Japan
- Volunteers
- 44 people
- Sponsor
- Bayer
Contraceptive, Oral, Hormonal
Cycle Control and Safety of E2-DRSP
The study will be performed as a multi-center, randomized, double-blind, parallel-group trial in fertile women aged between 18 and 35 years inclusive.
- Trial name
- NCT00653614
- Testing
- E2/DRSP (BAY 86-4891) dose 1 (SH T04984E), E2/DRSP (BAY 86-4891) dose 2 (80458739), E2/DRSP (BAY 86-4891) dose 3 (80458755)
- Where
- 25 sites in Germany
- Volunteers
- 635 people
- Sponsor
- Bayer
Carcinoma, Non-Small-Cell Lung
A Phase III Randomized, Double-blind, Placebo Controlled Trial Comparing the Efficacy of Gemcitabine, Cisplatin and Sorafenib to Gemcitabine, Cisplatin and Placebo in First-Line Treatment of Patients With Stage IIIb With Effusion and Stage IV Non-Small Cell Lung Cancer (NSCLC)
Evaluation of gemcitabine and cisplatin in combination with either sorafenib or placebo for the treatment of patients with advanced Non-Small Cell Lung Cancer (NSCLC)
- Trial name
- NEXUS (NCT00449033)
- Testing
- Sorafenib (Nexavar, BAY43-9006), Gemcitabine, Cisplatin
- Where
- 122 sites in Austria, Belgium and 16 more
- Volunteers
- 904 people
- Sponsor
- Bayer
Multiple Sclerosis, Relapsing-Remitting
BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose
The BEYOND Follow-Up study will give patients who participated in the preceding BEYOND study the opportunity to continue treatment with the 500µg dose of interferon beta (IFNB) 1b and will further investigate the safety and…
- Trial name
- Beyond (NCT00459667)
- Testing
- Interferon beta-1b (Betaseron, BAY86-5046)
- Where
- 184 sites in United States, Argentina and 24 more
- Volunteers
- 1,420 people
- Sponsor
- Bayer
Postmenopause
Effects of Wellnara on Climacteric Symptoms
Aim of this NIS is to obtain further information on efficacy, tolerability, and acceptance of Wellnara in a large user population under the conditions of routine medical practice.
- Trial name
- NCT00913926
- Testing
- E2/LNG oral (Wellnara, BAY86-5029)
- Where
- Germany
- Volunteers
- 749 people
- Sponsor
- Bayer
Therapeutic Equivalency
Bioequivalence Study in Healthy Subjects, 2*5 mg Tablets Rivaroxaban Versus 1*10 mg Tablet Rivaroxaban
The drug investigated in this study is Rivaroxaban, a novel, once-daily, oral anticoagulant for the prevention (prophylaxis) of deep vein thrombosis (DVT) which may lead to a pulmonary embolism (PE) in people undergoing knee or…
- Trial name
- NCT01436526
- Testing
- Rivaroxaban (Xarelto, BAY59-7939)
- Where
- Germany
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Bayer
Nulliparous
Scandinavian Mirena Insertion Nulliparous Trial.
In this non-interventional study we investigate the nulliparous women individual evaluation of the insertion procedure of LNG-IUD and the follow-up period of 3 months post insertion.
- Trial name
- NCT00798980
- Testing
- Mirena (BAY86-5028)
- Where
- Sweden
- Volunteers
- 224 people, healthy volunteers welcome
- Sponsor
- Bayer
Hemophilia A
Non-interventional Observation of Practical Implementation, Efficacy and Safety of Continuous Infusion With KOGENATE Bayer in Surgery
The objective of this international post-marketing surveillance study is to collect data on the efficacy and safety of continuous infusion with KOGENATE Bayer in surgery.
- Trial name
- NO PEACKS (NCT00922597)
- Testing
- Recombinant Factor VIII (Kogenate FS, BAY14-2222)
- Where
- 7 sites in Austria, Germany and 5 more
- Volunteers
- 26 people
- Sponsor
- Bayer
Overactive Bladder
FREEDOM - First Real-Life Evaluation of Enablex Done in ZA Overactive Bladder Patients During a 3 Months Period
Patient perspective on Overactive Bladder and symptoms experienced after administration of Darifenacin
- Trial name
- FREEDOM (NCT00921245)
- Testing
- Darifenacin (Emselex, BAY79-4998)
- Where
- South Africa
- Volunteers
- 9 people
- Sponsor
- Bayer
Atrial Fibrillation
Efficacy and Safety of Rivaroxaban for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation
This is a clinical study evaluating the efficacy and safety of rivaroxaban for stroke prevention in patients with atrial fibrillation (originally described in Japanese).
- Trial name
- NCT00494871
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Warfarin
- Where
- 165 sites in Japan
- Volunteers
- 1,280 people
- Sponsor
- Bayer
Neoplasms
Phase Ib Study of PI3(Phosphoinositol 3)-Kinase Inhibitor Copanlisib With MEK (Mitogen-activated Protein Kinase) Inhibitor Refametinib (BAY86-9766) in Patients With Advanced Cancer
The PI3K (phosphoinositol 3-Kinase) inhibitor Copanlisib and the MEK (mitogen-activated protein kinase) inhibitor Refametinib (BAY86-9766)have both been tested as single agent treatments in other phase I studies.
- Trial name
- NCT01392521
- Testing
- Copanlisib + Refametinib (BAY86-9766)
- Where
- 8 sites in United States, Germany and 1 more
- Volunteers
- 64 people
- Sponsor
- Bayer
Osteoporosis, Postmenopausal
Julina Post-marketing Surveillance for Postmenopausal Osteoporosis in Japan
This study is a regulatory post-marketing surveillance in Japan, and it is a local prospective and observational study of patients who have received Julina for postmenopausal osteoporosis.
- Trial name
- NCT01397955
- Testing
- E2 transdermal (Julina, BAY86-5435)
- Where
- Japan
- Volunteers
- 148 people
- Sponsor
- Bayer
Vasomotor System
ZK283197 for Treatment of Vasomotor Symptoms
The primary goal of the planned study is to investigate the efficacy and safety of ZK 283197 in the dosage of 2 and 3 mg ingested once daily during a period of 8 weeks for the treatment of hot flushes.
- Trial name
- NCT00537836
- Testing
- BAY 86-5310 (ZK 283197), 17ß-estradiol
- Where
- 4 sites in Germany, Netherlands and 1 more
- Volunteers
- 116 people
- Sponsor
- Bayer
Hypertension
Post-marketing Surveillance for Hypertensive Patients With Diabetes and/or Chronic Kidney Disease
This study is a post-marketing surveillance in Japan, and it is a local prospective, company sponsored and observational study of patient who have been treated by Adalat CR for hypertension with diabetes and/or chronic kidney…
- Trial name
- NCT01363336
- Testing
- Nifedipine (Adalat CR, BAYA1040)
- Where
- Japan
- Volunteers
- 1,882 people
- Sponsor
- Bayer
Anti-Infective Agents
Cross-over Study to Prove Bioequivalence Between Two Brands of Cefalexin Capsules
A single dose, two treatments (two cephalexin capsules brands), two sequences, cross-over design was used with a washout of 7 days between the two study periods.
- Trial name
- NCT01073553
- Testing
- Cephalexin capsules (Optocef, BAYO5448 ), Cephalexin capsules (Keflex)
- Where
- Mexico
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Bayer
Carcinoma, Hepatocellular
Safety Study of BAY73-4506 in Patients With Hepatocellular Carcinoma
The purpose of this study is to determine whether BAY73-4506 treatment is safe and can shrink or delay the growth of tumors in patients with unresectable liver cancer.
- Trial name
- NCT01003015
- Testing
- BAY73-4506
- Where
- 13 sites in Germany, Italy and 2 more
- Volunteers
- 36 people
- Sponsor
- Bayer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.